Chronic fatigue disorders: An inappropriate response to arginine vasopressin?

Medical Hypotheses

Volumn 50, Issue 6, 1998, Pages 521-523

  Peroutka, S J ^a  

^a Spectra Biomedical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOCORTICOID; VASOPRESSIN;

ARTICLE; CHRONIC FATIGUE SYNDROME; HORMONE INHIBITION; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LETHARGY; MENTAL DISEASE; PRIORITY JOURNAL; SALT LOADING; STEROID THERAPY; WATER METABOLISM;

EID: 0031800889     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90275-4     Document Type: Article

References (18)

1. Holmes G P, Kaplan J E, Gantz N M et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387-389.
2. Fukuda K, Straus S E, Hickie I, Sharpe M C, Dobbins J G, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-959.
3. Price R K, North C S, Wessely S, Fraser V J. Estimating the prevalence of chronic fatigue syndrome and associated symptoms in the community. Public Health Rep 1992; 107: 514-522.
4. Bou-Holaigah I, Rowe P C, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. J Am Med Assoc 1995; 274: 961-967.
5. Rowe P C, Bou-Holaigah I, Kan J S, Calkins H. Is neurally mediated hypotension an unrecognised cause of chronic fatigue? Lancet 1995; 345: 623-624.
6. Demitrack M A, Dale J K, Straus S E et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73: 1224-1234.
7. Levy M S, Power M H, Kepler E J. The specificity of the 'water test' as a diagnostic procedure in Addison's disease. J Clin Endocrinol 1946; 6: 607-632.
8. Adams R D. Lassitude and asthenia. In: Thorn G W, Adams R D, Braunwald E, Isselbacher K J, Petersdorf, eds. Principles of Internal Medicine. New York: McGraw-Hill, 1977: 72-75.
9. Bakheit A M O, Behan P O, Watson W S, Morton J J. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol Scand 1993; 87: 234-238.
10. Khokhar N. Inappropriate secretion of antidiuretic hormone. Postgrad Med 1977; 62: 73-79.
11. Streeten D H P, Moses A M, Miller M. Disorders of the neurohypophysis. In: Thorn G W, Adams R D, Braunwald E, Isselbacher K J, Petersdorf, eds. Principles of Internal Medicine. New York: McGraw-Hill, 1977: 490-501.
12. Haycock G B. The syndrome of inappropriate secretion of antidiuretic hormone. Pediatr Nephrol 1995; 9: 375-381.
13. McEwen O R. Salt loss as a common cause of ill-health in hot climates. Lancet 1935; 1: 1015.
14. Riggs A T, Dysken M W, Kim S W, Opsahl J A. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics 1991; 32: 133-148.
15. Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787-791.
16. Ohnishi A, Orita Y, Okahara R et al. Potent aquaretic agent: a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993; 92: 2653-2659.
17. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993; 44: 19-23.
18. Ohnishi A, Orita Y, Takagi N et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995; 27: 546-551.